← Back to Blog
Cancer Treatment

Sintilimab: CHMP Positive Opinion in Europe, Routine Use in China — Accessing Cancer Drugs Before EU Approval

OriEast Editorial Team•2026-11-15

Quick Answer

Use this page to quickly understand what kinds of topics we cover, who the content is most useful for, and where to go next.

Main topics
Cancer Treatment
Best for
The EMA's CHMP issued a positive opinion on sintilimab (Zybrivo) for non-squamous NSCLC in November 2026, while the same PD-1 inhibitor is already routine care in China. Here is how European patients can judge whether treatment in China makes sense now.
Best next step
Read Patient Guides

Need help applying this to your own case?

OriEast can help turn what you learned here into the right next step for hospital choice, records preparation, or travel planning.

How OriEast helps

We help international patients move from reading and research to real medical coordination in China.

  • ✓Clarify whether this topic is relevant to your case or travel plan
  • ✓Shortlist the right hospital, service, or specialist pathway
  • ✓Review records and reduce planning mistakes before booking
  • ✓Support hospital coordination, travel timing, and next-step questions

Your records are only shared as needed to coordinate planning and specialist review.

The European Medicines Agency published meeting highlights on 13 November 2026 covering its Committee for Medicinal Products for Human Use (CHMP) session of 9–12 November. Among the decisions recorded was a positive opinion on a new medicine marketed as Zybrivo — the PD-1 inhibitor sintilimab — for adults with non-squamous non-small cell lung cancer (NSCLC), submitted by Fortvita Biologics (Ireland) Limited. The molecule came out of the research pipeline of the Chinese company Junshi Biosciences, and it is not a new drug to Chinese oncologists: sintilimab is already a routinely available treatment option in Chinese hospital practice. That gap — an opinion in Europe, ordinary use in China — is what drives the most common question we receive from European readers: can I get this cancer drug in China before it is approved here? The answer is yes in some cases, with conditions, and the conditions matter more than the headline.

What a CHMP positive opinion does and does not change for patients

A CHMP positive opinion is a regulatory step, not a prescription. It tells the European Commission whether the agency recommends granting a marketing authorisation. Only after an authorisation exists — and after national pricing, reimbursement and hospital formulary decisions in the member state where you live — can a hospital pharmacy normally supply the medicine to your oncology team. So a patient in Berlin, Dublin or Madrid reading a November 2026 press release is looking at a leading indicator, typically months away from a ward.

The same meeting batch is a good illustration of how selective these headlines are. Alongside Zybrivo, the CHMP issued a positive opinion on Aumseqa, from SFL Pharmaceuticals Deutschland GmbH, also for adult NSCLC, and on Baxfendy, AstraZeneca's new medicine for hypertension. It also confirmed two rejections after re-examination, KemSu and Meplyffa, and listed multi-indication extensions including Gazyvaro. Notably, nothing China-derived in the CAR-T or bispecific antibody space appeared in these particular highlights. If you are comparing "China approved it first" as a general rule, treat it drug by drug: for this PD-1 inhibitor the gap is real, while other cell therapies and antibody formats follow entirely different timelines. Our guide to CAR-T therapy costs in China covers that separate question.

The same molecule, two access paths

DimensionEuropean Union, status reported by EMAChina
Regulatory milestoneCHMP positive opinion on Zybrivo (sintilimab) for adult non-squamous NSCLC, meeting of 9–12 November 2026Sintilimab is a routinely used PD-1 inhibitor in Chinese oncology practice
Who filed / who developedMarketing authorisation applicant: Fortvita Biologics (Ireland) LimitedOriginated from the R&D pipeline of Junshi Biosciences
Can a patient be prescribed it?Not on the strength of an opinion; authorisation plus national pricing and formulary decisions come firstPossible where the drug is on the treating hospital's formulary and the diagnosis matches the indication
What sets the priceNational pricing and reimbursement processes after authorisationThe hospital's current quotation, reflecting procurement status, formulary rules and pack size
Realistic first stepAsk your oncology team for the authorisation status in your countryVerify drug, indication and hospital stock, then request a clinical case review

Two points in that table are worth dwelling on. First, "available in China" and "available to you, as a foreign patient, at a specific hospital this month" are not the same statement. Registration is a national question; stock is a hospital question; and international patient access is a third question, usually handled by an international medical department rather than the general clinic queue. Second, the indication in the European news — adult non-squamous NSCLC — may not map line-for-line onto the indications used in Chinese practice, which is why the pathology report and staging summary, not the news article, should drive the decision. Our overview of cancer treatment in China for international patients sets out how those three questions are normally answered in sequence.

Which questions actually decide whether travel is worthwhile

Before spending money on flights, work through five questions in order. Stop the process if any one of them has a clear negative answer.

  1. Is the molecule registered in China for a relevant indication? This is a factual check against the drug's Chinese registration, and it is the only question the EMA news partially answers for you.
  2. Does the hospital you are considering carry the drug, and can its oncology department start it for an international patient? Formulary status changes without press releases.
  3. Is your disease status stable enough to travel and to wait between the first consultation and the first cycle? Performance status, organ function and symptoms determine this, not enthusiasm about a molecule.
  4. Can your diagnostic material travel with you? Reviewable pathology slides or blocks, imaging in original digital format, laboratory results and a dated summary of prior treatment are usually the minimum for a clinician to make an evidence-based judgement. Without them, a Chinese oncologist may need to repeat work, which adds cost and delay.
  5. What happens when you go home? Decide in advance who continues the cycles, who manages immune-related toxicity, and how the treating teams exchange records. A drug that is available in China is not much use if no one at home will continue it.

For most European patients, the realistic blockers are questions 4 and 5, not question 1. A broader framing of the same trade-offs is in the complete medical tourism guide for China, and the entry requirements are covered in the China medical visa guide.

Costs and timelines: what can honestly be planned

We are deliberately not publishing a price for sintilimab in this article. Drug pricing in China is set through procurement and hospital formulary mechanisms that change over time, and the figure that governs your decision is the treating department's current quotation for your regimen, cycle count and body-surface-based dosing. Anyone printing a single number for a multi-cycle immunotherapy course is guessing. What can be planned honestly is the structure of the spend:

Cost componentHow the real figure is determined
The PD-1 inhibitor itselfCurrent quotation from the prescribing hospital, per cycle
Day-care or inpatient administrationItemised hospital bill for each cycle
Pre-treatment workupImaging, laboratory panels and pathology review ordered by the oncologist
Monitoring for immune-related adverse eventsFollow-up visits and tests scheduled by the treating team
Interpreting and care coordinationAgreed in advance with OriEast as a fixed service scope
Travel and accommodationAirfare and lodging market rates for the chosen city and season

Timeline planning is similar. The sequence — document review, first appointment, staging confirmation, first cycle, then repeated cycles with safety bloods — is predictable; the intervals between them are set by your oncologist and the hospital's scheduling. European patients commonly compress their stay by completing the pre-treatment workup before travel, which is one of several practical reasons to book the first hospital appointment in Shanghai only after records have been reviewed. Note also the regulatory asymmetry in your favour here: a CHMP positive opinion does not shorten your waiting list at home, whereas availability in China is a present-tense fact. That asymmetry is worth something to a patient whose disease is progressing — but it should not be sold to you as a shortcut. No clinic can promise a response, and treatment decisions must be made by the physician who examines you.

Practical cautions specific to European patients

Bring documentation, not assumptions: an oncologist in China will weight a recent, dated, translated summary heavily, and vague or missing records usually mean repeated tests. Confirm with your national medicines authority whether you may bring a prescribed oncology medicine home for personal use, because that is a customs and pharmaceutical-law question separate from prescribing rules. Check your insurer or public health system in writing about pre-authorisation for treatment abroad, and ask what it will and will not cover on return. Finally, treat immune-related toxicity as a continuity problem rather than a theoretical risk: know who acts on the first fever, jaundice or breathlessness within your own healthcare system. And a wider note for readers following the news cycle: not every China-origin therapy lands in Europe — the same November 2026 CHMP highlights also confirmed rejections for KemSu and Meplyffa after re-examination, so early availability decisions elsewhere should rest on verified, drug-specific status rather than on a good headline. If your situation involves other modalities, our proton therapy guide and hospital directory explain how those separate decisions are structured.

A measured answer for the "can I get it in China now?" question

For sintilimab, the honest summary is this: the PD-1 inhibitor at the centre of the European news is already part of ordinary Chinese oncology practice, while European patients are at the opinion stage of a longer regulatory chain, and whether you personally should act on that gap depends on your pathology, your fitness to travel, hospital formulary status and the continuation plan at home. That is a clinical and logistical judgement. Specific treatment decisions, including whether immunotherapy is appropriate for you at all, must be made by a licensed physician after an in-person or documented case assessment.

OriEast supports international patients through exactly the practical layer that separates these two timelines: translation of medical records and consultations, hospital appointment booking with an international department, cost estimates from the treating hospital against your current clinical documents, and coordination while you are in China. If you are weighing a drug that is available in China but not yet authorised in your country, start with a case evaluation — send your diagnosis, staging, prior treatments and reports, and a clinician will review whether the drug, the indication and the hospital line up. For logistics, scheduling or a cost estimate, send an inquiry or contact us and we will tell you plainly when the answer is no.

Next step

If this topic is relevant to your treatment or travel plan, these pages are the best next place to continue.